{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T16:43:59Z","timestamp":1785861839578,"version":"3.56.0"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,3]]},"DOI":"10.1097\/cad.0b013e328011fd99","type":"journal-article","created":{"date-parts":[[2007,1,29]],"date-time":"2007-01-29T04:00:58Z","timestamp":1170043258000},"page":"273-276","source":"Crossref","is-referenced-by-count":7,"title":["An open-label, multicenter phase II trial of capecitabine in patients with cisplatin-refractory or relapsed germ cell tumors"],"prefix":"10.1097","volume":"18","author":[{"given":"Karin","family":"Oechsle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedemann","family":"Honecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Kollmannsberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Rick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Gr\u00fcnwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg T.","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Bokemeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20210203","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1200\/JCO.1990.8.11.1777","article-title":"Treatment of testicular cancer: a new and improved model","volume":"8","author":"Einhorn","year":"1990","journal-title":"J Clin Oncol"},{"key":"R2-5-20210203","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2165\/00003495-199958020-00004","article-title":"Diagnosis and treatment of patients with testicular germ cell cancer","volume":"58","author":"Hartmann","year":"1999","journal-title":"Drugs"},{"key":"R3-5-20210203","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/(SICI)1097-0142(19970101)79:1<161::AID-CNCR23>3.0.CO;2-1","article-title":"Long-term survival of patients with recurrent or refractory germ cell tumors after high dose chemotherapy","volume":"79","author":"Beyer","year":"1997","journal-title":"Cancer"},{"key":"R4-5-20210203","first-page":"36","article-title":"Phase II study of daily oral etoposide in refractory germ cell tumors","volume":"17","author":"Miller","year":"1990","journal-title":"Semin Oncol"},{"key":"R5-5-20210203","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1200\/JCO.1999.17.2.512","article-title":"Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer","volume":"17","author":"Bokemeyer","year":"1999","journal-title":"J Clin Oncol"},{"key":"R6-5-20210203","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1200\/JCO.1999.17.2.509","article-title":"Phase II trial of gemcitabine in refractory germ cell tumors","volume":"17","author":"Einhorn","year":"1999","journal-title":"J Clin Oncol"},{"key":"R7-5-20210203","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/oxfordjournals.annonc.a010473","article-title":"Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer","volume":"7","author":"Bokemeyer","year":"1996","journal-title":"Ann Oncol"},{"key":"R8-5-20210203","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1200\/JCO.2002.08.050","article-title":"Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group","volume":"20","author":"Kollmannsberger","year":"2002","journal-title":"J Clin Oncol"},{"key":"R9-5-20210203","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1093\/annonc\/mdh307","article-title":"Oxaliplatin in non-seminomatous germ-cell tumors","volume":"15","author":"Fizazi","year":"2004","journal-title":"Ann Oncol"},{"key":"R10-5-20210203","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1046\/j.1464-410x.2000.00660.x","article-title":"Angiogenesis and lymphangiogenesis in stage I germ cell tumors of the testis","volume":"86","author":"Jones","year":"2000","journal-title":"BJU Int"},{"key":"R12-5-20210203","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/0021-9681(61)90060-1","article-title":"The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent","volume":"13","author":"Gehan","year":"1961","journal-title":"J Chronic Dis"},{"key":"R13-5-20210203","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1016\/j.ejca.2006.03.013","article-title":"Activity of thalidomide in patients with platinum-refractory germ-cell tumours","volume":"42","author":"Rick","year":"2006","journal-title":"Eur J Cancer"},{"key":"R14-5-20210203","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1200\/JCO.2002.07.158","article-title":"Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumors (E9897): a trial of the Eastern Cooperative Oncology Group","volume":"20","author":"Hinton","year":"2002","journal-title":"J Clin Oncol"},{"key":"R15-5-20210203","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1200\/JCO.2004.06.068","article-title":"Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group","volume":"22","author":"Kollmannsberger","year":"2004","journal-title":"J Clin Oncol"},{"key":"R16-5-20210203","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/annonc\/mdh103","article-title":"Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors","volume":"15","author":"Pectasides","year":"2004","journal-title":"Ann Oncol"},{"key":"R17-5-20210203","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/00001813-200204000-00009","article-title":"Capecitabine in patients with breast cancer relapsing after high-dose chemotherapy plus autologous peripheral stem cell transplantation: a phase II study","volume":"13","author":"Jakob","year":"2002","journal-title":"Anticancer Drugs"}],"container-title":["Anti-Cancer Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CAD.0b013e328011fd99","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:43:58Z","timestamp":1785858238000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001813-200703000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/cad.0b013e328011fd99","relation":{},"ISSN":["0959-4973"],"issn-type":[{"value":"0959-4973","type":"print"}],"subject":[],"published":{"date-parts":[[2007,3]]}}}